139 related articles for article (PubMed ID: 12181427)
1. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.
Zhang W; Ke H; Colman RW
Mol Pharmacol; 2002 Sep; 62(3):514-20. PubMed ID: 12181427
[TBL] [Abstract][Full Text] [Related]
2. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
Zhang W; Ke H; Tretiakova AP; Jameson B; Colman RW
Protein Sci; 2001 Aug; 10(8):1481-9. PubMed ID: 11468344
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.
Shakur Y; Fong M; Hensley J; Cone J; Movsesian MA; Kambayashi J; Yoshitake M; Liu Y
Cardiovasc Drugs Ther; 2002 Sep; 16(5):417-27. PubMed ID: 12652111
[TBL] [Abstract][Full Text] [Related]
4. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
Zhang W; Colman RW
Blood; 2007 Sep; 110(5):1475-82. PubMed ID: 17392505
[TBL] [Abstract][Full Text] [Related]
5. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Wang S; Cone J; Fong M; Yoshitake M; Kambayashi Ji ; Liu Y
J Cardiovasc Pharmacol; 2001 Nov; 38(5):775-83. PubMed ID: 11602824
[TBL] [Abstract][Full Text] [Related]
6. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis.
Cheung PP; Yu L; Zhang H; Colman RW
Arch Biochem Biophys; 1998 Dec; 360(1):99-104. PubMed ID: 9826434
[TBL] [Abstract][Full Text] [Related]
7. Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis.
Colman RW
Semin Thromb Hemost; 2004 Aug; 30(4):451-60. PubMed ID: 15354266
[TBL] [Abstract][Full Text] [Related]
8. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
9. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Sudo T; Tachibana K; Toga K; Tochizawa S; Inoue Y; Kimura Y; Hidaka H
Biochem Pharmacol; 2000 Feb; 59(4):347-56. PubMed ID: 10644042
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
Nakamura K; Ikomi F; Ohhashi T
J Vasc Res; 2006; 43(1):86-94. PubMed ID: 16286783
[TBL] [Abstract][Full Text] [Related]
13. Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.
Tang KM; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 1)(Pt 1):217-24. PubMed ID: 9173884
[TBL] [Abstract][Full Text] [Related]
14. Conserved amino acids in metal-binding motifs of PDE3A are involved in substrate and inhibitor binding.
Zhang W; Colman RW
Blood; 2000 Jun; 95(11):3380-6. PubMed ID: 10828019
[TBL] [Abstract][Full Text] [Related]
15. Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3A in human spermatozoa.
Lefièvre L; de Lamirande E; Gagnon C
Biol Reprod; 2002 Aug; 67(2):423-30. PubMed ID: 12135876
[TBL] [Abstract][Full Text] [Related]
16. A nonhydrolyzable reactive cAMP analogue, (S(p))-8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 3',5'-cyclic S-(methyl)monophosphorothioate, irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase at micromolar concentrations.
Hung SH; Madhusoodanan KS; Boyd RL; Baldwin JL; Colman RF; Colman RW
Biochemistry; 2002 Mar; 41(9):2962-9. PubMed ID: 11863434
[TBL] [Abstract][Full Text] [Related]
17. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.
Sun B; Li H; Shakur Y; Hensley J; Hockman S; Kambayashi J; Manganiello VC; Liu Y
Cell Signal; 2007 Aug; 19(8):1765-71. PubMed ID: 17482796
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory action of cilostazol, a phosphodiesterase III inhibitor, on catecholamine secretion from cultured bovine adrenal chromaffin cells.
Azuma M; Houchi H; Mizuta M; Kinoshita M; Teraoka K; Minakuchi K
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S29-32. PubMed ID: 12688393
[TBL] [Abstract][Full Text] [Related]
19. Identification of inhibitor specificity determinants in a mammalian phosphodiesterase.
Atienza JM; Susanto D; Huang C; McCarty AS; Colicelli J
J Biol Chem; 1999 Feb; 274(8):4839-47. PubMed ID: 9988724
[TBL] [Abstract][Full Text] [Related]
20. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
